Rocket Pharmaceuticals Receives Orphan Medicinal Product Designation from the European Commission for RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy [Yahoo! Finance]
Rocket Pharmaceuticals, Inc. (RCKT)
Last rocket pharmaceuticals, inc. earnings: 3/5 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
rocketpharma.com
Company Research
Source: Yahoo! Finance
a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the European Commission (EC), based on a positive opinion issued by the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA), has granted orphan medicinal product designation for RP-A601, the Company's adeno-associated virus (AAV.rh74)-based gene therapy candidate for the treatment of plakophilin-2 related arrhythmogenic cardiomyopathy (PKP2-ACM). PKP2-ACM is a devastating, inherited heart disease associated with life-threatening arrhythmias, cardiac structural abnormalities, and sudden cardiac death. Presently, there are no curative treatment options available for PKP2-ACM. The current standard of care consists of medical therapy, implantable cardioverter defibrillators (ICDs), and ablation procedures. Even with treatment, life-threatening arrhythmias and progression of disease can still occur. PKP2-ACM affects approximately 50,000 people in the
Show less
Read more
Impact Snapshot
Event Time:
RCKT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RCKT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RCKT alerts
High impacting Rocket Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
RCKT
News
- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $52.00 price target on the stock.MarketBeat
- Rocket Pharmaceuticals Announces Completion of Enrollment in Phase 2 Pivotal Trial of RP-A501 for the Treatment of Danon DiseaseBusiness Wire
- Rocket Pharmaceuticals Announces Appointment of Mikael Dolsten, M.D., Ph.D., to Board of DirectorsBusiness Wire
- Rocket Stock Down More Than 30% in Past Six Months: Here's Why [Yahoo! Finance]Yahoo! Finance
- Rocket Pharmaceuticals to Participate in Upcoming Investor ConferencesBusiness Wire
RCKT
Earnings
- 8/5/24 - In-Line
RCKT
Sec Filings
- 9/11/24 - Form 4
- 9/11/24 - Form 8-K
- 9/11/24 - Form 3
- RCKT's page on the SEC website